Autres langues Foghorn Therapeutics Inc.

Actions

FHTX

US3441741077

Temps réel estimé Cboe BZX Autres places de cotation 18:11:18 02/05/2024			Varia. 5j.	Varia. 1 janv.
6,295 ^USD	+7,42%		+21,41%	-1,55%

09/04	Transcript : Foghorn Therapeutics Inc. - Special Call
07/03	Foghorn Therapeutics Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Foghorn Therapeutics Names Kristian Humer CFO	16/04
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer	16/04
Foghorn Therapeutics Inc. Appoints Kristian Humer as Chief Financial Officer	16/04
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs	09/04
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences	09/04
Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference	05/04
Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting	26/03
Foghorn Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook	07/03
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook	07/03
Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909	05/03
Foghorn Therapeutics Inc. to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, Including the Selective Inhibitor of BRM, FHD-909	05/03
Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference	28/02
Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference	28/02
Eli Lilly : un antitumoral de Foghorn a été sélectionné	08/02
Foghorn Shares Rally as Eli Lilly Plans Clinical Program With Oncology Product	08/02
Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor	08/02
Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor	08/02
Foghorn Therapeutics Inc. Appoints Stephen J. Dipalma Interim Chief Financial Officer, Effective January 16, 2024	17/01
Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024	08/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Foghorn Therapeutics Inc.

Actions

FHTX

US3441741077

Autres langues

Filtres